Targets › MRPL11
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on MRPL11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nanfang Hospital, Southern Medical University | Homoharringtonine (HHT) Protein synthesis inhibitor | MRPL11 | Phase 3 | Newly Diagnosed Acute Myeloid Leukemia With High Risk | Dec 2026 |
Newly Diagnosed Acute Myeloid Leukemia With High Risk (1)
small molecule (1)
Nanfang Hospital, Southern Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.